Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open-label Clinical Trial Assessing the Efficacy of Octreotide in Decreasing Blood and Iron Requirements in Patients With Refractory Anaemia Due to Angiodysplasias

Next Previous
Trial Profile

A Multicenter, Randomized, Open-label Clinical Trial Assessing the Efficacy of Octreotide in Decreasing Blood and Iron Requirements in Patients With Refractory Anaemia Due to Angiodysplasias

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Octreotide (Primary)
  • Indications Angiodysplasia
  • Focus Therapeutic Use
  • Acronyms OCEAN

Most Recent Events

  • 27 Dec 2023 Primary endpoint has been met, (The mean difference in blood and iron requirements.), as per published in the Gastroenterology
  • 27 Dec 2023 Results assessing the efficacy of octreotide in reducing the transfusion requirements of patients with angiodysplasia-related anemia, published in the Gastroenterology
  • 10 Aug 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top